About Uncharacterized protein C4orf17
Uncharacterized protein C4orf17 (C4orf17) is a protein
from Homo sapiens identified by UniProt accession
Q53FE4, 359 residues long.
MolForge cross-references it against 0 known binders and
16 disease associations.
Target properties
| Protein name | Uncharacterized protein C4orf17 |
| UniProt accession | Q53FE4 |
| Gene | C4orf17 |
| Organism | Homo sapiens |
| Length | 359 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (16)
Diseases linked to this target (Open Targets).
- alcohol consumption measurement · score 0.40
- viral load · score 0.30
- alcohol use disorder measurement · score 0.25
- apolipoprotein A 1 measurement · score 0.19
- body height · score 0.17
- triglyceride measurement · score 0.07
- serum alanine aminotransferase measurement · score 0.05
- alcohol dependence measurement · score 0.04
- platelet component distribution width · score 0.04
- aspartate aminotransferase measurement · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q53FE4-F1 | alphafold | PREDICTED | 56.18 | — |
Amino-acid sequence (359 residues)
MNLNPPTSAL QIEGKGSHIM ARNVSCFLVR HTPHPRRVCH IKGLNNIPIC TVNDDENAFG TLWGVGQSNY LEKNRIPFAN CSYPSSTAVQ ESPVRGMSPA PNGAKVPPRP HSEPSRKIKE CFKTSSENPL VIKKEEIKAK RPPSPPKACS TPGSCSSGMT STKNDVKANT ICIPNYLDQE IKILAKLCSI LHTDSLAEVL QWLLHATSKE KEWVSALIHS ELAEINLLTH HRRNTSMEPA AETGKPPTVK SPPTVKLPPN FTAKSKVLTR DTEGDQPTRV SSQGSEENKE VPKEAEHKPP LLIRRNNMKI PVAEYFSKPN SPPRPNTQES GSAKPVSARS IQEYNLCPQR ACYPSTHRR
Explore Uncharacterized protein C4orf17 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets